Table 1 Clinical and pathological characteristics of patient cohort
From: RRM2 expression in different molecular subtypes of breast cancer and its prognostic significance
Socio-demographic data | The studied group (n = 200) |
|---|---|
Age/ years | |
Mean ± SD | 58.14 ± 12.11 |
< 60 y | 109 (54.5%) |
≥ 60 y | 91 (45.5%) |
ER | |
Positive | 138 (69.0%) |
Negative | 62 (31.0%) |
PR | |
Positive | 124 (62.0%) |
Negative | 76 (38.0%) |
HER2 | |
Positive (score 3+) | 45 (22.5%) |
Negative | 155 (77.5%) |
Ki 67 Median (Min-Max) | 10 (2–60) |
Molecular Class | |
Luminal A | 75 (37.5%) |
Luminal B | 40 (20.0%) |
TN BLBC | 39 (19.5%) |
Her2 Luminal | 17 (8.5%) |
Her2 enriched | 29 (14.5%) |
EGFR | |
Positive | 150 (75.0%) |
Negative | 50 (25.0%) |
Histological type | |
Ductal | 173 (86.5%) |
TIL-rich IBC-NST | 4 (2.0%) |
Mucinous | 5 (2.5%) |
Lobular | 15 (7.5%) |
Micropapillary | 3 (1.5%) |
Grade (n = 173) | |
I | 3 (1.7%) |
II | 136 (78.6%) |
III | 34 (19.7%) |
Multicentricity | |
Positive | 6 (3.0%) |
Negative | 194 (97.0%) |
Tumour size | |
T1 | 13 (6.5%) |
T2 | 134 (67.0%) |
T3 | 51 (25.5%) |
T4 | 2 (1.0%) |
Lymph node | |
No | 47 (23.5%) |
N1 | 60 (30.0%) |
N2 | 49 (24.5%) |
N3 | 44 (22.0%) |
Tumour stage | |
I | 4 (2.0%) |
II | 90 (45.0%) |
III | 106 (53.0%) |
Recurrence | |
Yes | 61 (30.5%) |
No | 139 (69.5%) |
Time of follow up Median (Min-Max) | 50 (1–85) |
Time of recurrence Median (Min-Max) | 32 (1–85) |
RRM2 score | |
Negative | 45 (22.5%) |
Mild | 10 (5.0%) |
Moderate | 86 (43.0%) |
Intense | 59 (29.5%) |